BioCity was established in December 2017. It is an innovative drug company created by local entrepreneurs who have a deep understanding of the Chinese pharmaceutical market and young returned scientists relying on the world's leading open drug innovation platform.

The company is committed to the discovery, development and commercialization of novel or highly differentiated candidates (with no modality limitation) to treat diseases with significant unmet medical needs, particularly cancers and Nephropathy.

Through internal research, open innovation platform and collaborations, BioCity has established a pipeline of more than 10 innovative programs including small molecules, monoclonal and bispecific antibodies as well as antibody-drug conjugate (ADCs).